» Articles » PMID: 38824173

Interaction Analysis of Subgroup Effects in Randomized Trials: the Essential Methodological Points

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jun 1
PMID 38824173
Authors
Affiliations
Soon will be listed here.
Abstract

Subgroup analysis aims to identify subgroups (usually defined by baseline/demographic characteristics), who would (or not) benefit from an intervention under specific conditions. Often performed post hoc (not pre-specified in the protocol), subgroup analyses are prone to elevated type I error due to multiple testing, inadequate power, and inappropriate statistical interpretation. Aside from the well-known Bonferroni correction, subgroup treatment interaction tests can provide useful information to support the hypothesis. Using data from a previously published randomized trial where a p value of 0.015 was found for the comparison between standard and Hemopatch® groups in (the subgroup of) 135 patients who had hand-sewn pancreatic stump closure we first sought to determine whether there was interaction between the number and proportion of the dependent event of interest (POPF) among the subgroup population (patients with hand-sewn stump closure and use of Hemopatch®), Next, we calculated the relative excess risk due to interaction (RERI) and the "attributable proportion" (AP). The p value of the interaction was p = 0.034, the RERI was - 0.77 (p = 0.0204) (the probability of POPF was 0.77 because of the interaction), the RERI was 13% (patients are 13% less likely to sustain POPF because of the interaction), and the AP was - 0.616 (61.6% of patients who did not develop POPF did so because of the interaction). Although no causality can be implied, Hemopatch® may potentially decrease the POPF after distal pancreatectomy when the stump is closed hand-sewn. The hypothesis generated by our subgroup analysis requires confirmation by a specific, randomized trial, including only patients undergoing hand-sewn closure of the pancreatic stump after distal pancreatectomy.Trial registration: INS-621000-0760.

Citing Articles

Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century.

Janani L, Phillips R, Van Vogt E, Liu X, Waddington C, Cro S Clin Exp Immunol. 2024; 219(1).

PMID: 39570146 PMC: 11754867. DOI: 10.1093/cei/uxae104.

References
1.
Rothwell P . Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005; 365(9454):176-86. DOI: 10.1016/S0140-6736(05)17709-5. View

2.
Lagakos S . The challenge of subgroup analyses--reporting without distorting. N Engl J Med. 2006; 354(16):1667-9. DOI: 10.1056/NEJMp068070. View

3.
Chaouch M, Dziri C, Uranues S, Fingerhut A . Pancreatic stump closure after distal pancreatectomy: Systematic review and meta-analysis of randomized clinical trials comparing non-autologous versus no reinforcement: Value of prediction intervals. Am J Surg. 2024; 229:92-98. DOI: 10.1016/j.amjsurg.2023.12.030. View

4.
Pisapia A, Crolla E, Saracco M, Saglioccolo A, Dolce P, Molino C . The effectiveness of Hemopatch™ in preventing postoperative distal pancreatectomy fistulas. Expert Rev Med Devices. 2019; 16(3):253-256. DOI: 10.1080/17434440.2019.1582328. View

5.
Sun X, Briel M, Busse J, You J, Akl E, Mejza F . Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ. 2012; 344:e1553. DOI: 10.1136/bmj.e1553. View